CureVac's founder Ingmar Hoerr is considered one of the pioneers in mRNA technology. For a long time, the potential of mRNAs was conceivable, but it was not until the pandemic and the first approved mRNA-based vaccines that the incredible potential behind mRNAs became clear. CureVac is currently in Phase III development of its Covid-19 vaccine, approval is planned for the summer, and a fast-track approval in Germany is currently the subject of heated political debate.
It would be the third approved mRNA vaccine worldwide, the second from a German company. Our keynote speaker Stefan Mueller is VP Pre-Cinical Development and COVID-19 Program Lead and can therefore give a perfect overview of the state of development, challenges and difficulties.
The keynote will take place on April 29 between 12 and 12:30 pm.